CSI Market
Sign In | Register

Rapport Therapeutics Inc (RAPP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RAPP Annual Cash Flow →
Tracking cash flow results across Rapport Therapeutics Inc to Jun 30 2025 helps illustrate how Jun 30 2026's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-76.47
Depreciation & amortization0.44
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation14.17
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Change In Fair Value Of Preferred Stock Tranche Right Liability-
Operating Lease Right Of Use Asset Amortization Expense0.58
Increase Decrease In Operating Lease Liabilities-0.68
Non- Cash Loss On Sale Of Property And Equipment0.15
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.29
Increase (Decrease) in Accounts Payable-1.37
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities11.09
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.34
Other Working Capital-0.35
Other Noncash Income (Expense)0.00
Other net0.02
Payments for (Proceeds from) Other Operating Activities-4.67
Discontinued operations0.00
Net Cash flow from Operating Activities-54.52
Investing Activities
Capital Expenditures-0.16
Sale of Capital Items0.19
Proceeds from Sale of Short-term Investments10.08
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments53.44
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities63.54
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.45
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.40
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.01
Proceeds From Initial Public Offering And Concurrent Private Placement Net Of Underwriter Discounts And Commissions And Deferred Offering Costs-
Settlement Of Series A Preferred Stock Tranche Right Liability-
Deferred Offering Costs-
Conversion Of Stock Amount Converted-
Noncash Or Part Noncash Acquisition Fixed Assets Acquired0.05
Payments For Repurchase Of Unvested Restricted Common Stock-0.01
Proceeds From Underwritten Public Offering Net Of Underwriter Discounts And Commissions And Deferred Offering Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.94
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-54.49
Total Cash Flow10.97
4 historic quarters locked

Sign in to unlock the full Rapport Therapeutics Inc cash flow history.

Sign In Create Free Account

About Rapport Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-333862

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Get the full CSIMarket dataset: Subscribe API License